Furthermore, despite the availability of several next-generation TKIs, crizotinib remains a first-line treatment option for patients with advanced ALK-positive NSCLC 15 and is widely used in cases where next-generation TKIs are not yet approved or are economically inaccessible. The gene discussed is ALK; the disease is non-small cell lung carcinoma.